Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mineralocorticoid Receptor Antagonist Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

NCT04019652
View directory record Official record
Conditions
Hypertension, Mineralocorticoid Receptor Antagonist
Interventions
CS-3150, Moxifloxacin, Placebo matching moxifloxacin tablet, Placebo matching CS-3150
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 30, 2026, 9:08 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Eplerenone and IOP in Healthy Adults

NCT07795762
View directory record Official record
Conditions
Intraocular Pressure (IOP), Healthy Adult
Interventions
Eplerenone, Microcrystalline Cellulose NF (placebo)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease

NCT02497300
View directory record Official record
Conditions
Chronic Kidney Disease, Albuminuria
Interventions
Spironolactone, Amiloride
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Not applicable Interventional

Pragmatic Trial Of Alerts for Use of Mineralocorticoid Receptor Antagonists

NCT04903717
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Best Practice Alert
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1,210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Not applicable Interventional Results available

Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure (BETTER CARE-HF)

NCT05275920
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction
Interventions
Best Practice Alert (BPA), In-Basket Message
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
2,211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 30, 2026, 9:08 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

NCT06033950
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone, Placebo
Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
18 Years and older
Enrollment
2,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
54
States / cities
Fairhope, Alabama • Phoenix, Arizona • Yuma, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Not applicable Interventional Results available

Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)

NCT02740179
View directory record Official record
Conditions
HIV
Interventions
Eplerenone, Placebo, Lifestyle Modification
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance

NCT02585843
View directory record Official record
Conditions
Heart Failure
Interventions
Spironolactone 100mg, Spironolactone 25mg
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Sep 30, 2026, 9:08 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)

NCT04300881
View directory record Official record
Conditions
Vitreomacular Traction, Subretinal Edema
Interventions
Eplerenone
Drug
Lead sponsor
Wagner Macula & Retina Center
Other
Eligibility
19 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Informational Nudge to Improve Heart Failure Prescribing

NCT05986695
View directory record Official record
Conditions
Heart Failure
Interventions
Alert, Peer comparison report
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Completed No phase listed Observational

A Study Using Surveys to Learn More About Treatment With Steroidal Mineralocorticoid Receptor Antagonists, How They Are Used, What Side Effects They Have, and How Satisfied People Who Receive Them Are in the US

NCT05407662
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus, Heart Failure
Interventions
sMRA therapies
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 4 Interventional Results available

Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity

NCT04519164
View directory record Official record
Conditions
Metabolic Syndrome, Hypertension, Overweight and Obesity
Interventions
Eplerenone, Chlorthalidone with potassium chloride
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

NCT04435626
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone (BAY94-8862), Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
6,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
107
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN

NCT03683069
View directory record Official record
Conditions
Hypertension, Genetics Hypertension
Interventions
Eplerenone vs Amlodipine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 30, 2026, 9:08 AM EDT
Not yet recruiting Not applicable Interventional

RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)

NCT07605390
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Epic-Based Clinician Notification, Usual Care
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Active, not recruiting Phase 4 Interventional

MR Antagonist and LSD1

NCT04840342
View directory record Official record
Conditions
Hypertension, Mineralocorticoid Excess
Interventions
Eplerenone, Amlodipine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
17 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Completed No phase listed Observational

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

NCT05526157
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions
Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Steroidal mineral corticoid receptor antagonists (sMRA), Non-steroidal mineral corticoid receptor antagonists (nsMRA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers

NCT01314898
View directory record Official record
Conditions
Healthy Volunteers
Interventions
3 mg PF-03882845, 10 mg PF-03882845, 30 mg PF-03882845, 100 mg PF-03882845, Spironolactone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 6, 2011 · Synced Sep 30, 2026, 9:08 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

NCT04968184
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Placebo, KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
65
States / cities
Foley, Alabama • Huntsville, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 30, 2026, 9:08 AM EDT
Not yet recruiting Phase 4 Interventional

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

NCT07547878
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Withdrawn Not applicable Interventional

Email Nudges to Improve GDMT (MRA) Adherence in Heart Failure

NCT05806970
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Email Nudge
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 30, 2026, 9:08 AM EDT
Completed No phase listed Observational

Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure

NCT05077293
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction
Interventions
Best Practice Alert (BPA), In-Basket Message
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Sep 30, 2026, 9:08 AM EDT